The efficacy of PD1 blockade is reliant upon disrupting interactions between PD1-positive T cells and PD-L1-positive melanoma cells [29,30], ultimately leading to the expansion of tumor neoantigen-specific clones and tumor control. Here, PDCD1 is linked to melanoma.